05 Jul 06
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
29 Jun 06
The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules.
27 Jun 06
Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
27 Jun 06
While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.
21 Jun 06
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
20 Jun 06
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
19 Jun 06
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets.
19 Jun 06
In today's edition of DailyUpdates we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus
16 Jun 06
In today's edition of DailyUpdates we headline with news from CuraGen and TopoTarget on a new trial evaluating the combination of an HDAC inhibitor an cis-retinoid acid. In addition we highlight research from Wyeth suggesting a new approach to depression
14 Jun 06
Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Olwen Glynn Owen - PharmiWeb Field Reporter
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.